FrancophonIA/ELRC3.0 huggingface dataset:
English: The solvent in Profender spot-on solution may stain certain materials including leather, fabrics, plastics and finished surfaces, so contact between the product and such surfaces should be avoided.
Maltese: Is-solvent f'soluzzjoni għal użu lokalizzat ta' Profender jista' jtebba' ċerti materjali fosthom ġilda, drappijiet, plastiks u superfiċji lesti, u għalhekk għandu jiġi evitat kull kuntatt bejn il-prodott u dawn is-superfiċji.
English: Profender is a medicine used to treat cats and dogs that have, or are at risk of catching, “mixed” (caused by more than one parasite) parasitic infections.
Maltese: Profender jintuża fil-kura ta' klieb u qtates li jsofru minn infezzjonijiet ikkaġunati minn parassiti “diversi” (kkawżati minn aktar minn parassita wieħed) jew li jkunu f'riskju li jiġu infettati minnhom.
English: Dogs are treated using Profender modified-release tablets, which are given by mouth when the dog is fasting.
Maltese: Il-klieb jiġu kkurati bil-pilloli ta' rilaxx modifikat ta' Profender, li jingħataw b'mod orali meta l-kelb ikun qed isum.
English: Profender tablets are available in three different strengths to cover a range of dog weights (small, medium or large dogs).
Maltese: Il-pilloli ta' Profender jiġu fi tliet qawwiet differenti biex ikopru firxa ta' piżijiet differenti (klieb ta' żgħar, medji jew kbar).
English: What are the risks associated with Profender?
Maltese: X'inhuma r-riskji assoċjati ma' Profender?
English: Other information about Profender:
Maltese: Aktar tagħrif dwar Profender:
English: Profender solution is packed as spot-on pipettes, which are already filled with the correct amount of Profender needed to treat one cat (3 sizes of pipette for different cat weights) and as a multidose bottle for use only in a veterinary surgery, where the vet will measure the exact volume of Profender needed for each cat before application.
Maltese: L-effikaċja ta' kull wieħed mill-prodotti kontra l-ħniex u d-dud speċifiċikati ġiet investigata kemm fi studji f'laboratorju kif ukoll fi studji ta' skala wiesgħa (wieħed fuq l-użu lokalizzat għall-qtates u ieħor fuq il-pilloli għall-klieb) li saru ġo bosta lokalitajiet differenti fl-Ewropa kollha.
English: Over 90% of cats and 99% of dogs had no roundworm or tapeworm infection after treatment with Profender.
Maltese: Wara l-kura bi Profender aktar minn 90% tal-qtates u 99% tal-klieb ma baqgħux isofru minn infezzjonijiet mill-ħniex jew mid-dud.
English: Profender solution is packed as spot-on pipettes, which are already filled with the correct amount of Profender needed to treat one cat (3 sizes of pipette for different cat weights) and as a multidose
Maltese: Il-pilloli ta' Profender jiġu fi tliet qawwiet differenti biex ikopru firxa ta' piżijiet differenti (klieb ta' daqs żgħir, medju jew kbir).
English: Profender works for infections caused by certain types of roundworms, tapeworms, as well as lungworms in cats.
Maltese: Profender jaħdem fuq infezzjonijiet ikkawżati minn ċerti tipi ta' ħniex, dud, kif ukoll lungworms filqtates.
English: Praziquantel damages the skin-like outer layer of tapeworms, leading to their paralysis and death.
Maltese: Lemodepside tinterferixxi ma' ċerti riċetturi speċifiċi fis-sistemi nervużi tad-dud, li jirriżulta fil-paraliżi u l-mewt tagħhom.
English: Profender is available as a solution for use on cats, and as modified release tablets for dogs.
Maltese: Profender ma għandux jintuża fuq xi speċijiet ta' annimali oħrajn.
English: The appropriate quantity of Profender (either the contents of one full pipette or the volume measured by the vet) is applied onto the cat's skin, after parting the fur on the back of its neck at the base of its head.
Maltese: Il-kwantità adegwata ta' Profender (il-kontenut ta' pipetta mimlija jew il-volum imkejjel mill-veterinarju) tiġi applikata fuq il-ġilda tal-qattus, wara li jitferraq il-pil fuqani tal-għonq fit-tarf saflieni ta' rasu.
English: Adopted at the 30 November - 3 December 2015 PRAC
Maltese: Adottata fit-30 ta' Novembru - 3 ta' Diċembru 2015 PRAC
English: TACHOSIL (Human fibrinogen, human thrombin)Intestinal obstruction (EPITT no 18373)
Maltese: TACHOSIL (Fibrinoġen uman, trombin uman) - Ostruzzjoni intestinali (EPITT Nru 18373)
English: Hormone replacement therapy (HRT) medicinal products, which are not pharmaceutical forms for vaginal use, containing oestrogens or combined oestrogens-progestagens (tibolone containing products also concerned); DUAVIVE (bazedoxifene, oestrogens conjugated) - Increased risk of ovarian cancer (EPITT no 18258)
Maltese: Prodotti mediċinali terapewtiċi ta' sostituzzjoni tal-ormoni (Hormone replacement therapy, HRT), li mhumiex forom farmaċewtiċi għall-użu fil-vaġina, fihom estroġeni jew estroġeni-proġestaġeni kkombinati (prodotti li fihom tibolone huma wkoll ikkonċernati); DUAVIVE (bazedoxifene, estroġeni kkonjugati) - Riskju miżjud ta' kanċer tal-ovarji (EPITT nru
English: Frequency ‘unknown': Intestinal obstruction (in abdominal surgeries) General disorders and administration site conditions: Frequency ‘unknown': Adhesions
Maltese: Frekwenza "mhux magħrufa": Ostruzzjoni intestinali (f'kirurġiji addominali) Disturbi ġenerali u kondizzjonijiet ta' mnejn jingħata Frekwenza "mhux magħrufa": Adeżjonijiet
English: In the Million Women Study, taking 5 years of HRT tibolone resulted in 1 extra case per 2500 users (see Section 4.4).
Maltese: Fl-Istudju ta' Miljun Mara, li persuna tieħu l-HRT għall-5 snin tiboloneirriżulta f'każ addizzjonali għal kull 2500 utent (ara Sezzjoni 4.4).
English: Events of adhesions to gastrointestinal tissues leading to gastrointestinal obstruction have been reported with use in abdominal surgery carried out in proximity to the bowel.
Maltese: Okkażjonijiet ta' adeżjonijiet għal tessuti gastrointestinali li jwasslu għal ostruzzjoni gastrointestinali ġew irrapportati bl-użu f'kirurġija addominali mwettqa qrib l-imsaren.
English: BEFORE YOU TAKE DUVAVIVE
Maltese: 2. QABEL MA TIEĦU DUVAVIVE
English: In the Million Women Study 5 years of HRT resulted in 1 extra case per 2500 users.
Maltese: FlIstudju ta' Miljun Mara, 5 snin ta' HRT irriżultaw f'każ addizzjonali għal kull 2500 utent.
English: After abdominal surgery and if TachoSil sticks to nearby tissues, it is possible that scar tissues can develop in the operated area.
Maltese: Wara kirurġija addominali u jekk TachoSil jeħel ma' tessut fil-qrib, huwa possibbli li jiżviluppaw tessuti mmakkjati fiż-żona operata.
English: It is important to note that failure to adequately clean adjacent tissues may cause adhesions (see section 4.4).
Maltese: Huwa importanti li jiġi nnotat li nuqqas li wieħed inaddaf it-tessuti li jmissu miegħu jista' jikkawża adeżjonijiet (ara sezzjoni 4.4).
English: In the Million Women Study, it was shown that the relative risk for ovarian cancer with use of tibolone was similar to the risk associated with use of other types of HRT.
Maltese: Fl-Istudju ta' Miljun Mara, intwera li r-riskju relattiv għall-kanċer tal-ovarji bl-użu ta' tibolone kien simili għar-riskju assoċjat b'użu ta' tipi oħrajn ta' HRT.
English: Long-term (at least 5-10 years) use of oestrogen-only HRT products has been associated with a slightly increased risk of ovarian cancer (see section 4.8).
Maltese: L-użu fit-tul (tal-inqas 5-10 snin) ta' prodotti HRT b'estroġenu biss ġie assoċjat ma' żieda żgħira fir-riskju ta' kanċer tal-ovarji (ara sezzjoni 4.8).
English: Some other studies, including the Women's Health Initiative (WHI) trial, suggest that the longterm use of combined HRTs may confer be associated with a similar, or slightly smaller risk (see Section 4.8).
Maltese: Xi studji oħrajn, li jinkludu l-prova tal-Women's Health Initiative (WHI) , jissuġġerixxu li l-użu fittul ta' HRTs ikkombinati jista' jikkonferixxi ikun assoċjat ma' riskju simili jew ftit iżgħar (ara Sezzjoni 4.8).
English: Instructions for Use
Maltese: Twissijiet u prekawzjonijiet
English: Package Leaflet 2.
Maltese: 2. QABEL MA TIEĦU PLENADREN
English: The risk of ovarian cancer varies with age.
Maltese: Ir-riskju ta' kanċer tal-ovarji jvarja skont l-età.
English: New product information wording - Extracts from PRAC recommendations on signals
Maltese: Għall-prodotti li fihom it-tibolone
English: For example, in A slightly increased risk of ovarian cancer has been reported in women taking HRT for at least 5 to 10 years.Compare For women aged 50 to 5469 who are not taking HRT, on average about 2 women in 21000 will be diagnosed with ovarian cancer over a 5-year period.
Maltese: Meta-analiżi minn 52 studju epidemijoloġiku rrapportat żieda fir-riskju tal-kanċer tal-ovarji fin-nisa li bħalissa qegħdin jużaw l-HRT meta mqabbla ma' nisa li qatt ma għamlu użu mill-HRT (RR 1.43, 95% CI 1.31-1.56) L-Istudju ta' Miljun Mara Għal nisa li għandhom minn 50 sa 54 sena li ilhom jieħdu l-HRT għal 5 snin, dan jirriżultaa f'madwar każ addizzjonali f'kull 2,5000 utent.
English: For oestrogen only and combined oestrogen-progestagen HRT products
Maltese: Effetti mhux mixtieqa Kanċer tal-ovarji
English: Long term uUse of estrogen-only and or combined estrogen-progestogen HRT has been associated with a slightly increased risk of having ovarian cancer diagnosed (see Section 4.4).
Maltese: L-użu fit-tul uUta' HRT estroġenu biss ġie assoċjat ma' żieda żgħira fir-riskju li persuna tkundijanjostikata bil-kanċer tal-ovarji (ara Sezzjoni 4.4) .
English: To prevent the development of tissue adhesions at undesired sites, ensure tissue areas outside the desired application area are adequately cleansed before administration of TachoSil (see section 6.6).
Maltese: 4.4 Twissijiet speċjali u prekawzjonijiet għall-użu Biex timpedixxi l-iżvilupp ta' adeżjonijiet tat-tessut f'siti mhux mixtieqa, agħmel ċert li żoni tat-tessut barra miż-żona tal-applikazzjoni jitnaddfu b'mod adegwat qabel l-applikazzjoni ta' TachoSil (ara sezzjoni 6.6).
English: Other adverse reactions have been reported in association with oestrogen and oestrogenprogestogen treatment:
Maltese: Effetti mhux mixtieqa Ġew irrapportati reazzjonijiet avversi oħrajn b'assoċjazzjoni ma' kura b'estroġenu/proġestoġenu.
English: This study showed that the relative risk for ovarian cancer with tibolone was similar to the risk with other types of HRT.
Maltese: Dan l-istudju wera li r-riskju relattiv għall-kanċer tal-ovarji mat-tibolone kien simili għar-riskju b'tipi oħra ta' HRT.
English: For women aged 50 to 54 years taking 5 years of HRT, this results in about 1 extra case per 2000 users.
Maltese: Għan-nisa li għandhom bejn 50 sa 54 sena u li ilhom jieħdu l-HRT għal ħames snin, dan jirriżulta bejn wieħed u ieħor f'każ addizzjonali wieħed għal kull 2000 utent.
English: Scar tissues may develop in some patients after surgery and use of TachoSil.
Maltese: Il-kirurgu tiegħek sejjer jagħmel ċert li jnaddaf iż-żona tal-operazzjoni meta japplika TachoSil biex inaqqas dan ir-riskju.
English: For women who have been taking HRT for 5 years, there will be between 2 and about 3 cases per 21,000 users (i.e. about up to 1 extra case).
Maltese: Għal nisa li ilhom jieħdu HRT għal 5 snin, ser ikun hemm bejn 2 u madwar 3 każijiet f'kull 21,000 utent (jiġifieri sa każ wieħed addizzjonali).
English: Some other studies, including the WHI trial, suggest that the long-term use of combined HRTs may confer be associated with a similar, or slightly smaller risk (see Section 4.8).
Maltese: Xi studji oħrajn, inkluża l-prova WHI, jissuġerixxu li l-użu ta' HRTs flimkien jistgħu jiġu assoċjati ma' riskju simili jew ma' riskju daqsxejn iżgħar (ara Sezzjoni 4.8) L-effett ta' DUAVIVE fuq ir-riskju tal-kanċer tal-ovarji mhuwiex magħruf.
English: SmPC
Maltese: 3. Għal DUAVIVE
English: For DUAVIVE product
Maltese: Struzzjonijiet għall-Użu
English: For women who have been taking HRT for 5 years, there will be between 2 and about 3 cases per 21000 users (i.e. up to about 1 extra case).
Maltese: Għal nisa li ilhom jieħdu HRT għal 5 snin, ser ikun hemm bejn 2 u madwar 3 każijiet f'kull 21000 utent (jiġifieri sa bejn wieħed u ieħor każ wieħed addizzjonali).
English: Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only or combined oestrogen-progestagen HRT, which becomes apparent within 5 years of use and diminishes over time after stopping.
Maltese: Evidenza epidemijoloġika minn meta-analiżi kbira tissuġġerixxi riskju kemmxejn miżjud fin-nisa li jieħdu HRT b'estroġeni biss jew b'estroġeni u proġestaġeni flimkien, li jibda jidher fi żmien 5 snin ta' użu u jitnaqqas maż-żmien wara li jkun twaqqaf.
English: Summary of product characteristics (SmPC) section 4.4: Special warnings and precautions for use
Maltese: Għall-estroġeni biss u għall-prodotti HRT ta' estroġeni u proġestaġeni kkombinati Sommarju tal-Karatteristiċi tal-Prodott (SPC) is-sezzjoni 4.4: Twissijiet speċjali u prekawzjonijiet għall-użu
English: Bowel obstruction and pain following abdominal surgeries can also occur.
Maltese: Jistgħu jseħħu wkoll ostruzzjoni tal-imsaren u uġigħ wara kirurġiji addominali.
English: For example, in Wwomen aged 50 to 5469 who are not taking HRT, on average about 2 women in 21000 will be diagnosed with ovarian cancer over a 5year period.
Maltese: Pereżempju, f' nisa li għandhom minn 50 sa 5469 li mhumiex qed jieħdu l-HRT, bħala medjamadwar 2 nisa minn kull 21,000 sejrin jiġu dijanjostikati bil-kanċer tal-ovarji fuq perjodu ta' 5 snin.
English: A slightly increased risk of ovarian cancer has been reported in women taking HRT for at least 5 to 10 years.
Maltese: Ġiet irrapportata żieda żgħira fir-riskju ta' kanċer tal-ovarji f'nisa li jieħdu HRT għal tal-inqas 5 sa 10 snin.
English: Scar tissues can cause surfaces in your bowel to stick together, which can lead to blockage of the bowel.
Maltese: Kanċer tal-ovarji huwa ħafna aktar rari minn kanċer tas-sider.
English: Some other studies, including the WHI trial, suggest that use of combined HRTs may be associated with a similar or slightly smaller risk (see Section 4.8).
Maltese: Xi studji oħrajn, li jinkludu prova WHI, jissuġġerixxu li l-użu fit-tul ta' HRTs flimkien tista' tikkonferixxi tkun assoċjata ma' riskju simili jew ftit iżgħar (ara Sezzjoni 4.8).
English: SmPC section 4.4: Special warnings and precautions for use Ovarian cancer
Maltese: Ara s-sezzjoni 4.8 tal-SPC.
English: Vial (glass) 0.5 ml (1 dose)
Maltese: 0,5 ml (1 doża)
English: Inactivated Rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037: ≥70% cELISA40* (*) ≥=70% of vaccinated rabbits shall give cELISA antibody titres equal to or higher than 40.
Maltese: ≥70% cELISA40* (*) ≥70 % tal-fniek imlaqqma għandhom jagħtu titri tal-antikopri cELISA ugwali għal jew ogħla minn 40.
English: 10 vials Zero days
Maltese: 10 kunjetti Xejn
English: 50 to <200 200 to <350
Maltese: 50 sa <200 200 sa <350
English: GSK Services Sp. z o.o.
Maltese: Polska GSK Services Sp. z o.o.
English: Protease Inhibitors Atazanavir
Maltese: Inibituri ta' Protease Atazanavir
English: Resistance in vivo
Maltese: Reżistenza in vivo
English: Extremadura 3, 09400 Aranda De Duero, Burgos, Spain OR
Maltese: Extremadura 3, 09400 Aranda De Duero, Burgos, Spanja Jew:
English: OSS: combined genotypic and phenotypic resistance (Monogram Biosciences Net Assessment)
Maltese: OSS: reżistenza ġenotipika u fenotipika kombinati (Monogram Biosciences Net Assessment)
English: Anticonvulsants Carbamazepine
Maltese: Antikonvulsanti Carbamazepine
English: ViiV Healthcare BV Huis ter Heideweg 62 3705 LZ Zeist Netherlands
Maltese: ViiV Healthcare BV Huis ter Heideweg 62 3705 LZ Zeist L-Olanda
English: Iron oxide yellow (E172) (for 25 mg and 50 mg tablets)
Maltese: Iron oxide yellow (E172) (għall-pilloli ta' 25 mg u 50 mg)
English: Oral contraceptives Ethinyl estradiol (EE) and Norelgestromin (NGMN)
Maltese: Ethinyl estradiol (EE) u Norgestromin (NGMN)
English: (cps/mL)
Maltese: kopja/mL)
English: Resistance in vitro
Maltese: Reżistenza in vitro
English: Corticosteroids Prednisone
Maltese: Kortikosterojdi Prednisone
English: TIVICAY ~1 mg/kg Once Daily + OBR
Maltese: TIVICAY ~1 mg/kg Darba Kuljum + OBR
English: • hyperactivity (excessive restlessness and movement)
Maltese: • attività eċċessiva (irrekwitezza u moviment eċċessivi)
English: 15 to less than 20
Maltese: 15 sa inqas minn 20
English: People may be more likely to get this condition:
Maltese: Persuni jistgħu jkunu aktar probabbli li taqbadhom din ilkundizzjoni:
English: • itching (pruritus)
Maltese: • ħakk (pruritus)
English: Extremadura 3, 09400 Aranda de Duero, Burgos, Spain GlaxoSmithKline Pharmaceuticals S.A., ul., Grunwaldzka 189, 60-322 Poznan, Poland.
Maltese: Extremadura 3, 09400 Aranda de Duero, Burgos, Spanja GlaxoSmithKline Pharmaceuticals S.A., ul., Grunwaldzka 189, 60-322 Poznan, Il-Polonja
English: GlaxoSmithKline Pharmaceuticals S.A., ul., Grunwaldzka 189, 60-322 Poznan, Poland.
Maltese: GlaxoSmithKline Pharmaceuticals S.A., ul., Grunwaldzka 189, 60-322 Poznan, Il-Polonja
English: Interaction table
Maltese: Tabella tal-interazzjonijiet
English: • etravirine, efavirenz, fosamprenavir/ritonavir, nevirapine or tipranavir/ritonavir, to treat HIV infection
Maltese: • etravirine, efavirenz, fosamprenavir/ritonavir, nevirapine jew tipranavir/ritonavir, għall kura ta' infezzjoni tal-HIV
English: Antiviral activity in cell culture
Maltese: Attività antivirali f'kultura ta' ċelloli
English: †Other clades included: Complex (43), F1 (32), A1 (18), BF (14), all others <10.
Maltese: Il-kumpless (43), F1 (32), A1 (18), BF (14), l-oħrajn kollha <10.
English: Cohort IIA (6 to <12 years) (n=23)
Maltese: Koorti IIA (6 sa <12-il sena) (n=23)
English: 30 to less than 40
Maltese: 30 sa inqas minn 40
English: Date of latest renewal: 21 September 2018
Maltese: Data ta' l-aħħar tiġdid: 21 ta' Settembru 2018
English: Dolutegravir is present in cerebrospinal fluid (CSF).
Maltese: Dolutegravir huwa preżenti fil-fluwidu ċerebrospinali (CSF).
English: Cohort I (12 to <18 years) (n=23)
Maltese: Koorti I (12 sa <18il sena) (n=23)
English: Multivitamin
Maltese: Multivitamini
English: Uncommon Hepatitis Rare
Maltese: Mhux komuni Epatite Rari
English: 20 to less than 30
Maltese: 20 sa inqas minn 30
English: • rifampicin, to treat tuberculosis (TB) and other bacterial infections
Maltese: • rifampicin, għall-kura tat-tuberkulożi (TB) u infezzjonijiet batteriċi oħra
English: The adjusted difference in proportion and 95% CI were 7.1% (0.9, 13.2), p=0.025.
Maltese: Id-differenza aġġustata fil-proporzjon u 95% CI kienu 7.1% (0.9, 13.2), p=0.025.
English: Baseline CD4+ (cells/ mm3) 200 to <350 NRTI backbone ABC/3TC
Maltese: mm3) 200 to <350 NRTI backbone ABC/3TC
English: Pharmacokinetic data for dolutegravir in subjects >65 years of age are limited.
Maltese: Dejta farmakokinetika għal dolutegravir f'persuni ta' >65 sena hija limitata.
English: EFV/TDF/FTC Once Daily N=419
Maltese: EFV/TDF/FTC Darba Kuljum N=419
English: At week 48, 12/30 (40%) subjects had HIV-1 RNA <50 copies/mL (ITT-E, Snapshot algorithm).
Maltese: Fil-ġimgħa 48, 12/30 (40%) individwu kellhom HIV-1 RNA <50 kopja/mL (ITT-E, Algoritmu snapshot).
English: - The other ingredients are mannitol (E421), microcrystalline cellulose, povidone (K29/32), sodium starch glycolate, sodium stearyl fumarate, polyvinyl alcohol-partially hydrolyzed, titanium dioxide (E171), macrogol, talc and for 25 and 50 mg tablets, iron oxide yellow (E172).
Maltese: - Is-sustanzi l-oħra huma mannitol (E421), microcrystalline cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, polyvinyl alcohol-partially hydrolyzed, titanium dioxide (E171), macrogol, talc u għall-pilloli ta' 25 mg u 50 mg, iron oxide yellow (E172).
English: Based on the lack of effect on the in vivo pharmacokinetics of the OAT substrate tenofovir, in vivo inhibition of OAT1 is unlikely.
Maltese: Abbażi tan-nuqqas ta' effett tal-farmakokinetika in vivo tas-substrat ta' OAT tenofovir, mhix probabbli inibizzjoni in vivo ta' OAT1.
English: 2 N155H, Y143C/H/R, T66A, E92Q
Maltese: 2 N155H, Y143C/H/R, T66A, E92Q 3 G140A/C/S, E138A/K/T, L74I
English: If possible, show them the Tivicay pack.
Maltese: Jekk ikun possibbli, urihom il-pakkett ta' Tivicay.
English: • increase in the level of enzymes produced in the muscles (creatine phosphokinase).
Maltese: • żieda fil-livell tal-enzimi prodotti fil-muskoli (creatine phosphokinase).
English: Clade C
Maltese: ta' Klassi C.
English: Primary mutation other than Q148H/K/R2
Maltese: L-ebda mutazzjoni Q148H/K/R2
English: Established and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in Table 2.
Maltese: L-interazzjonijiet stabbiliti u teoretiċi ma' prodotti mediċinali antiretrovirali u mhux antiretrovirali huma elenkati f'Tabella 2.
English: Baseline with ongoing RAL/EVG
Maltese: RAL/EVG kontinwu
English: GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
Maltese: Eesti GlaxoSmithKline Eesti OÜ Tel: + 372 6676 900 estonia@gsk.com
English: Primary mutations for raltegravir/elvitegravir (Q148H/R/K, N155H, Y143R/H/C, E92Q and T66I) do not affect the in vitro susceptibility of dolutegravir as single mutations.
Maltese: Il-mutazzjonijiet primarji għal raltegravir/elvitegravir (Q148H/R/K, N155H, Y143R/H/C, E92Q u T66I) ma jaffettwawx is-suxxettibilità in vitro ta' dolutegravir bħala mutazzjonijiet uniċi.
English: In subtype C (n=2) and A/G (n=2) isolates the integrase substitution R263K was selected in one isolate, and G118R in two isolates.
Maltese: F'iżolati tas-sottotip C (n=2) u A/G (n=2), is-sostituzzjoni ta' integrase R263K intgħażlet f'iżolat wieħed, u G118R f'żewġ iżolati.
English: Common Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) elevations Common Creatine phosphokinase (CPK) elevations
Maltese: Żidiet fl-alanine aminotransferase (ALT) u/jew flaspartate aminotransferase (AST) elevations
English: Herbal products St. John's wort
Maltese: John's wort
English: Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Maltese: <1/100), rari (≥1/10,000 sa <1/1,000), rari ħafna (<1/10,000).
English: Dolutegravir ↑ AUC ↑ 91% Cmax ↑ 50% Cτ ↑ 180%
Maltese: Dolutegravir ↑ AUC ↑ 91% Cmax ↑ 50%
English: RAL 400 mg Twice Daily + BR N=361§
Maltese: RAL 400 mg Darbtejn Kuljum + BR N=361§
English: In vitro, dolutegravir inhibited the renal organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter (MATE) 1.
Maltese: In vitro, dolutegravir inibixxa t-trasportatur tal-kazzjonijiet organiċi 2 (OCT2) tal-kliewi u ttrasportatur tal-estrużjoni tal-multimediċini u t-tossini (MATE) 1.
English: 6.2 Incompatibilities Not applicable.
Maltese: .2 Inkompatibbiltajiet
English: Dolutegravir ↔ (Not studied)
Maltese: Dolutegravir ↔ (Mhix studjata)
English: What Tivicay contains - The active substance is dolutegravir.
Maltese: X'fih Tivicay - Is-sustanza attiva hi dolutegravir.
English: Sixteen of 30 subjects (53%) harboured Q148 virus at baseline.
Maltese: Sittax minn 30 individwu (53%) kellhom virus Q148 fil-linja bażi.
English: ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com
Maltese: Deutschland ViiV Healthcare GmbH Tel.: + 49 (0)89 203 0038-10 viiv.med.info@viivhealthcare.com
English: Dolutegravir is highly bound (>99%) to human plasma proteins based on in vitro data.
Maltese: Dolutegravir jeħel ħafna (>99%) mal-proteini tal-plażma tal-bniedem skont dejta in vitro.
English: HIV-1 RNA <50 copies/mL at 24 weeks, n (%) HIV-1 RNA <50 copies/mL at 48 weeks, n (%) HIV-1 RNA <400 copies/mL at 24 weeks, n (%) HIV-1 RNA <400 copies/mL at 48 weeks, n (%) Virologic non response
Maltese: HIV-1 RNA <50 kopja/mL wara 24 ġimgħa, n (%) HIV-1 RNA <50 kopja/mL wara 48 ġimgħa, n (%) HIV-1 RNA <400 kopja/mL wara 24 ġimgħa, n (%) HIV-1 RNA <400 kopja/mL wara 48 ġimgħa, n (%)
English: **see below under Description of selected adverse reactions.
Maltese: **ara hawn isfel taħt Deskrizzjoni ta' għażla ta' reazzjonijiet avversi.
English: • phenytoin and phenobarbital, to treat epilepsy
Maltese: • phenytoin u phenobarbital, għall-kura tal-epilessija
English: • oxcarbazepine and carbamazepine, to treat epilepsy or bipolar disorder
Maltese: • oxcarbazepine u carbamazepine, għall-kura tal-epilessija jew disturb bipolari